tiprankstipranks
Trending News
More News >
Natural Beauty Bio-Technology (HK:0157)
:0157
Advertisement

Natural Beauty Bio-Technology (0157) AI Stock Analysis

Compare
0 Followers

Top Page

HK:0157

Natural Beauty Bio-Technology

(OTC:0157)

Rating:48Neutral
Price Target:
HK$0.50
▼(-7.41%Downside)
The overall stock score reflects significant financial performance challenges, offset slightly by positive technical momentum. Negative valuation due to lack of profitability and no dividend yield also weigh heavily on the score.

Natural Beauty Bio-Technology (0157) vs. iShares MSCI Hong Kong ETF (EWH)

Natural Beauty Bio-Technology Business Overview & Revenue Model

Company DescriptionNatural Beauty Bio-Technology (0157) is a company that operates within the cosmetics and skincare industry, focusing on the development, manufacturing, and distribution of beauty and skincare products. The company leverages advanced biotechnology to create innovative and natural products catering to the personal care needs of consumers. Its core offerings include a range of skincare solutions, cosmetics, and health supplements designed to enhance beauty and well-being.
How the Company Makes MoneyNatural Beauty Bio-Technology generates revenue primarily through the sale of its beauty and skincare products. The company utilizes a multi-channel distribution strategy, including retail partnerships, e-commerce platforms, and direct-to-consumer sales. Additionally, it may engage in strategic partnerships with other companies in the beauty and health sectors to expand its market reach and enhance product offerings. Revenue is driven by consumer demand for high-quality, natural, and effective skincare solutions, and the company invests in research and development to continually innovate and introduce new products to the market.

Natural Beauty Bio-Technology Financial Statement Overview

Summary
The company is facing significant financial challenges with declining revenue and profitability. Increased leverage and negative cash flow trends indicate financial instability.
Income Statement
32
Negative
The company has experienced a decline in revenue from 2021 to 2024, indicating negative growth. Gross profit margins have decreased while net profit margins are negative, showing a lack of profitability. EBIT and EBITDA margins have worsened significantly, marking a challenging operating environment.
Balance Sheet
55
Neutral
The debt-to-equity ratio has increased over the years, reflecting rising leverage, yet it remains manageable. The equity ratio has decreased slightly, suggesting a decline in asset financing through equity. Return on equity is negative due to net losses, which is a concern for profitability.
Cash Flow
40
Negative
The company has seen a negative trend in free cash flow, with significant declines from 2021 to 2024. The operating cash flow to net income ratio is negative, indicating operational challenges. Free cash flow to net income ratio also reflects cash flow difficulties, hindering financial flexibility.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue353.65M336.01M335.88M487.81M410.67M
Gross Profit202.33M200.34M165.33M281.80M217.22M
EBITDA-65.50M22.91M15.09M85.23M41.57M
Net Income-103.61M-15.11M-30.47M35.26M7.76M
Balance Sheet
Total Assets772.93M882.58M883.53M937.16M840.77M
Cash, Cash Equivalents and Short-Term Investments116.51M166.81M168.61M197.08M165.61M
Total Debt212.13M186.29M143.48M129.07M75.02M
Total Liabilities325.34M308.06M286.07M279.24M229.54M
Stockholders Equity447.59M574.52M597.46M657.92M611.23M
Cash Flow
Free Cash Flow-54.96M-47.39M-35.98M4.67M-43.77M
Operating Cash Flow-13.75M21.72M8.33M42.78M30.09M
Investing Cash Flow-40.17M-67.61M-43.98M-31.21M-50.63M
Financing Cash Flow15.34M42.63M18.10M14.31M29.85M

Natural Beauty Bio-Technology Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.54
Price Trends
50DMA
0.53
Negative
100DMA
0.50
Positive
200DMA
0.50
Positive
Market Momentum
MACD
<0.01
Positive
RSI
43.59
Neutral
STOCH
11.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0157, the sentiment is Neutral. The current price of 0.54 is below the 20-day moving average (MA) of 0.55, above the 50-day MA of 0.53, and above the 200-day MA of 0.50, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 43.59 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0157.

Natural Beauty Bio-Technology Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
HK$31.01B35.3137.28%2.18%59.83%68.29%
68
Neutral
HK$502.25M3.9124.41%5.38%22.46%91.73%
64
Neutral
HK$842.47M12.128.96%30.72%-35.61%
61
Neutral
HK$461.19M11.235.25%5.82%-23.89%
61
Neutral
HK$21.08B12.390.81%4.52%2.72%-47.45%
48
Neutral
HK$1.04B-20.26%5.25%-581.58%
48
Neutral
HK$24.21B-7.87%2.49%16.82%-348.71%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0157
Natural Beauty Bio-Technology
0.53
0.03
6.00%
HK:6993
Blue Moon Group Holdings Ltd.
4.02
2.05
104.06%
HK:3332
Nanjing Sinolife United Co., Ltd. Class H
0.48
-0.27
-36.00%
HK:2177
UNQ Holdings Limited
2.77
1.54
125.20%
HK:2145
Shanghai Chicmax Cosmetics Co., Ltd. Class H
76.40
40.04
110.12%
HK:1925
Kwung's Holdings Limited
1.23
0.16
14.95%

Natural Beauty Bio-Technology Corporate Events

Natural Beauty Bio-Technology Schedules Board Meeting for Interim Results
Jul 18, 2025

Natural Beauty Bio-Technology Limited has announced a board meeting scheduled for August 5, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend, which could impact shareholder returns and market perception of the company’s financial health.

Natural Beauty Bio-Technology Reports Strong Revenue Growth and Profit Turnaround
Jul 16, 2025

Natural Beauty Bio-Technology Limited announced a significant financial turnaround for the first half of 2025, with expected revenues of approximately HK$270 million, marking a 72% increase from the previous year. This growth is attributed to the company’s strategic expansion in the Mainland China market and improved operational efficiencies, leading to a projected net profit of HK$10 million, compared to a net loss in the same period last year.

Natural Beauty Bio-Technology Unanimously Passes AGM Resolutions
May 22, 2025

Natural Beauty Bio-Technology Limited held its Annual General Meeting on May 22, 2025, where all proposed resolutions were unanimously passed. These resolutions included the approval of financial statements, re-election of directors, and granting mandates for share repurchase and issuance, indicating strong shareholder support and strategic flexibility for the company.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 19, 2025